Goldilocks-inspired macrocycles FM648, FM636, and FM635 selectively target human MC4R
Background
The melanocortin system, particularly the melanocortin receptors (MCRs), plays a crucial role in regulating energy homeostasis, metabolism, and inflammation. Despite the clinical success of macrocyclic peptides like bremelanotide and setmelanotide in targeting MCRs, achieving high selectivity among the five MCR subtypes (MC1R-MC5R) with optimal pharmacological profiles remains a significant challenge. Current therapeutic strategies often lack the precision needed to avoid off-target effects, highlighting a critical gap for developing selective ligands for specific MCRs, especially MC4R, which is central to metabolic regulation.
Study Design
Researchers designed and synthesized a series of 14 novel macrocyclic peptide analogs with 19-23-membered rings. These compounds were based on established melanocortin peptide scaffolds, specifically MT-II, SHU-9119, and PG-901. The pharmacological activities of these newly synthesized macrocycles were systematically assessed in vitro using human MC1R, MC3R, MC4R, and MC5R to determine their potency and selectivity as either agonists or antagonists. This comprehensive screening aimed to identify compounds with optimized receptor-specific profiles.
Results
From the series of 14 novel macrocyclic peptide analogs, several compounds demonstrated significant and selective activity at human melanocortin receptors. Specifically, FM648 and FM636 emerged as potent and selective antagonists for hMC4R. This finding is crucial given the role of MC4R in metabolic regulation. Furthermore, FM635 exhibited interesting agonist activity, also with remarkable selectivity for hMC4R. The study successfully identified distinct compounds capable of both antagonizing and agonizing hMC4R with high specificity, a key challenge in melanocortin research. This tailored approach to midsized macrocycles provides valuable insights into the structure-activity relationships necessary for achieving receptor selectivity. > The novel macrocyclic compounds FM648 and FM636 emerged as potent and selective hMC4R antagonists, while FM635 exhibited interesting agonist activity with remarkable selectivity for the same receptor.
Key Findings
- 14 novel macrocyclic peptide analogs (19-23-membered rings) were synthesized based on MT-II, SHU-9119, and PG-901 scaffolds.
- FM648 and FM636 were identified as potent and selective
hMC4Rantagonists. - FM635 was identified as an interesting and remarkably selective
hMC4Ragonist. - Tailored midsized macrocycles show potential as selective MCR ligands.
- New insights into structure-activity relationships for selective MCR targeting were gained.
Why It Matters
This study significantly advances the field by demonstrating that tailored midsized macrocycles can achieve high selectivity for specific melanocortin receptors, particularly MC4R. For peptide users and biohackers, this research highlights the potential for developing highly targeted interventions for metabolic and inflammatory diseases with reduced off-target effects. The identification of both MC4R agonists and antagonists (FM635 vs. FM648/FM636) provides a versatile toolkit for future therapeutic development, potentially enabling more precise modulation of the melanocortin system. While currently an in-vitro study, these findings lay the groundwork for future preclinical and clinical candidates, suggesting a pathway towards more effective and safer treatments by leveraging the 'Goldilocks' properties of macrocyclic peptides.
melanocortin-receptors
mc4r
macrocycles
metabolic-disease
inflammatory-disease
in-vitro